Aptosyn exisulind: Phase II/III

Cell Pathways Inc. (CLPA), Horsham, Penn.
Product: Aptosyn exisulind
Business: Cancer
Therapeutic category: Apoptosis
Target: cGMP-PDE
Description: Oral sulfone metabolite of

Read the full 210 word article

How to gain access

Continue reading with a
two-week free trial.